Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 8;22(5):e237119.
doi: 10.6004/jnccn.2023.7119.

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events

Sarah E Fayle  1 , Nicolas L Palaskas  2 , Bilal A Siddiqui  3 , Jennifer L McQuade  4 , Jamie S Lin  5 , Sumit K Subudhi  3 , Anisha B Patel  6 , Robert R Jenq  7 , Amishi Y Shah  3 , Amy R Spelman  1 , Mianen Sun  1 , Bettina H Marble  8 , Yinghong Wang  9
Affiliations

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events

Sarah E Fayle et al. J Natl Compr Canc Netw. .

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for many cancer types. The clinical use of ICIs is increasing rapidly, including in combinations associated with increased risk of toxicities, termed "immune-related adverse events" (irAEs). Therefore, MD Anderson Cancer Center (MDACC) in Houston, Texas has proactively responded by developing a priority endeavor known as the Immuno-Oncology Toxicity (IOTOX) initiative. This strategic initiative aims to facilitate the seamless integration of key domains: (1) standardized clinical practice and innovative decision toolsets; (2) patient and provider education; and (3) a comprehensive clinical and translational research platform. The ultimate goal of this initiative is to develop and disseminate clinical best practices and biologic insights into irAEs to improve outcomes of patients with irAEs at MDACC and in the wider oncology community.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
The annual count of patients who received ICI treatment at MD Anderson from 2010, along with the corresponding percentage increase compared to the previous year. Additionally, projected patient numbers for ICI treatment from 2023 to 2025 are presented based on a forecasting model.
Figure 2:
Figure 2:
The distribution of IOTOX case numbers at MDACC in 2019 and 2022, categorized by organ toxicity. Each bar represents a specific toxicity case count.
Figure 3:
Figure 3:
A timeline of MDACC’s IOTOX initiative efforts, encompassing clinical, educational, and research activities.
Figure 4:
Figure 4:
The future direction of MDACC’s IOTOX initiative will advance across clinical, educational, and research dimensions.
See this image and copyright information in PMC

References

    1. Sharma P, et al. , The Next Decade of Immune Checkpoint Therapy. Cancer Discov, 2021. 11(4): p. 838–857. - PubMed
    1. Naing A, et al. , Strategies for improving the management of immune-related adverse events. J Immunother Cancer, 2020. 8(2). - PMC - PubMed
    1. Schneider BJ, et al. , Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol, 2021. 39(36): p. 4073–4126. - PubMed
    1. Thompson JA, et al. , Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2022. 20(4): p. 387–405. - PubMed
    1. Brahmer JR, et al. , Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer, 2021. 9(6). - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources